announced on Friday alongside its partner, Iterchimica, a world leader in products that enhance asphalt performance, the commencement of their UK road trial for graphene enhanced road surfaces.
According to Founder and CEO of Directa, Giulio Cesareo, the trial is considered crucial “in proving the business and use case for the next generation of graphene enhanced road surfaces.”
The trial, to take place in Curbridge, Oxfordshire, will involve laying asphalt concrete with a proprietary graphene-enhanced modifier to refurb two upper layers of a 750m long section of road.
By comparing asphalt concrete with the super modifier to a traditional asphalt surfacing, the trial will assess service life, resistance to the passage of vehicles, resistance to deformation and permanent plastic deformation.
Oxfordshire County Council has permitted the commencement of the trial, and the group’s prime contractor will be Skanska AB, a multinational construction company.
The graphene-enhanced modifier is the result of a three-year research with a patent filed in 2017 and has the potential to vastly improve the quality of road surfaces.
"This technology will allow governments to supply better quality roads for drivers and other road users, at better value for money, and in a more environmentally sustainable way,” commented Mr Cesareo.
Significantly, asphalt concrete with super modifier, once laid, can be 100% recycled, reducing the extraction of new materials from quarries and first-use bitumen.
"Working with leading companies such as Iterchemica to bring the benefits of G+ graphene enhanced products and materials to market is a key part of Directa Plus' strategy across all our key industrial verticals,” Mr Cesareo added.
Follow News & Updates from Directa Plus here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
SP Angel research note on commodities and miners, featuring: Adriatic Metals* (ADT AU) – Rupice metallurgical results BHP (BHP LN) – Half-Year Production report BlueRock Diamonds* (BRD LN) – Achieves profitable operations during H2 2019 Base Resources (BSE LN) – Assays indicate likely high-grade extension to Toliara project in Madagascar Caledonia Mining (CMCL LN) – Increased holding in the Blanket gold mine Highland Gold (HGM LN) – 300.7koz produced in FY19 v 290-300koz guided Jangada Mines (JAN LN) – drilling starts at vanadium property Premier African Minerals* (PREM LN) – Power supply connected at RHA Sunstone Metals Limited (STM AU) - Bramaderos Main assays extend strike length of mineralisation to 650m
Following a strong 2019, the vertically integrated business announced that its wholly-owned subsidiary, Labskin, had signed an MOU with Shanghai-based Innocare Group to assist with commercial enterprises in China.
In an earlier January trading statement, Joules had warned investors that annual profits would be ‘significantly’ lower than expected following an internal issue during ‘the important end’ of the season sale.
BAE Systems has spent £1.7 billion on two defence businesses that will help it expand in the US, Fevertree Drinks was being tipped as a potential bid target last night after a warning over poor Christmas trading sent its shares tumbling by more than a quarter
The International Monetary Fund the has revised down global growth slightly for 2020 by 0.1% to 3.3% and down by 0.2% to 3.4% for 2021. The downward revision was mostly due to lower growth in India, the U.K. is expected to expand by 1.3% and 1.4% for 2020 and 2021.
The global medical technology company said its workstations are used for diagnosing Hypoxic-Ischaemic Encephalopathy, a brain injury induced by oxygen deprivation to the brain in the newborn.